Seminars in arthritis and rheumatism最新文献

{"title":"Risk of major adverse cardiovascular events following targeted therapy in patients with rheumatoid arthritis: a real-world analysis stratified by cardiovascular risk","authors":"Seung-Hun You ,&nbsp;Soo-Kyung Cho ,&nbsp;Jeong-Yeon Kim ,&nbsp;Yeo-Jin Song ,&nbsp;Sun-Young Jung ,&nbsp;Yoon-Kyoung Sung","doi":"10.1016/j.semarthrit.2025.152721","DOIUrl":"10.1016/j.semarthrit.2025.152721","url":null,"abstract":"<div><h3>Objective</h3><div>To assess the risk of major adverse cardiovascular events (MACEs) associated with Janus kinase inhibitors (JAKi) compared to tumour necrosis factor inhibitors (TNFi) in rheumatoid arthritis (RA).</div></div><div><h3>Methods</h3><div>Using the Korean nationwide claims database, we identified patients with RA prescribed JAKi or TNFi between 2015 and 2019. Patients were stratified into two groups based on cardiovascular (CV) risk and matched within each group using propensity score matching at a ratio of up to 1:4. Follow-up continued until MACE, death, or treatment discontinuation. Hazard ratios with 95 % confidence intervals were calculated using the Cox proportional hazards model. Additionally, MACE risk was analyzed separately in patients with and without a history of cardiovascular disease (Hx.CVD).</div></div><div><h3>Results</h3><div>A total of 7575 patients prescribed either JAKi or TNFi were included. After propensity score matching, the hazard ratio for MACEs comparing JAKi to TNFi was 0.77 (95 % confidence interval 0.45–1.34) in the high CV risk group. No significant differences in MACEs were observed between JAKi and TNFi users across the low CV risk group, as well as Hx.CVD and non-Hx.CVD groups. Subgroup and sensitivity analyses showed no statistically significant differences in the risk of individual MACE components, such as myocardial infarction, stroke, or heart failure.</div></div><div><h3>Conclusion</h3><div>No significant differences in the risk of MACEs were observed between JAKi and TNFi users across various CV risk groups and in those with or without Hx.CVD. Subgroup and sensitivity analyses supported these findings, showing no elevated risks for individual MACE components.</div></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"73 ","pages":"Article 152721"},"PeriodicalIF":4.6,"publicationDate":"2025-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143858803","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predicting anxiety and depression in systemic lupus erythematosus: the role of inflammation, sociodemographic variables and clinical factors","authors":"Margot Sigel ,&nbsp;Carolina Muñoz-Grajales ,&nbsp;Michelle L. Barraclough ,&nbsp;Juan P Diaz-Martinez ,&nbsp;Mahta Kakvan ,&nbsp;Roberta Pozzi Kretzmann ,&nbsp;M Carmela Tartaglia ,&nbsp;Lesley Ruttan ,&nbsp;May Y Choi ,&nbsp;Simone Appenzeller ,&nbsp;Dennisse Bonilla ,&nbsp;Patricia Katz ,&nbsp;Dorcas E. Beaton ,&nbsp;Robin Green ,&nbsp;Dafna D. Gladman ,&nbsp;Joan E. Wither ,&nbsp;Alastair J. Flint ,&nbsp;Zahi Touma ,&nbsp;Kathleen S. Bingham","doi":"10.1016/j.semarthrit.2025.152718","DOIUrl":"10.1016/j.semarthrit.2025.152718","url":null,"abstract":"<div><h3>Objectives</h3><div>Characterizing the contribution of specific pro-inflammatory mediators (analytes) to depression and anxiety in systemic lupus erythematosus (SLE) is a crucial step in illuminating the mechanisms of these disabling symptoms. The aims of this study were to investigate i) the relationship between depression and anxiety symptoms with relevant clinical and sociodemographic variables and neuroinflammation-associated analytes in a cohort of SLE patients, and ii) the ability of models including these sociodemographic, clinical and biological variables to discriminate between SLE patients with and without clinically significant depression or anxiety.</div></div><div><h3>Methods</h3><div>This is a cross-sectional study of baseline data from participants enrolled in a longitudinal study of cognition in SLE (<em>N</em> = 238). We examined the relationship between serum concentrations of a group of analytes associated with neuroinflammation, relevant sociodemographic and clinical variables and i) depression (measured with the Beck Depression Inventory-II) and anxiety (measured with the Beck Anxiety Inventory) scores, as well as between clinically significant depression and anxiety symptoms (defined using cut-off scores validated in SLE) via random forests. We generated model performance statistics from these models using confusion matrices.</div></div><div><h3>Results</h3><div>Depression is most influenced by duration of SLE and, to a lesser extent, concentrations of the analytes MMP-9. Anxiety is most influenced by the analytes NGAL and IFN- Ɣ, with other variables being less influential. The multivariate models exhibited AUCs of 0.85 (depression), 0.77 (anxiety) and 0.82 (both depression and anxiety).</div></div><div><h3>Conclusions</h3><div>The findings of this exploratory study provide potential models predicting depression and anxiety symptoms in SLE. This produces a basis for further research building a conceptual model explaining the mechanisms of these important patient-centered outcomes in SLE.</div></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"73 ","pages":"Article 152718"},"PeriodicalIF":4.6,"publicationDate":"2025-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143874147","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"New anti-TNF biologics in RA: What is new and what is old?","authors":"Tsutomu Takeuchi","doi":"10.1016/j.semarthrit.2025.152693","DOIUrl":"10.1016/j.semarthrit.2025.152693","url":null,"abstract":"<div><div>This review summarizes the recent advancement of fragmented immunoglobulin molecules targeting on Tumot Necrosis Factor (TNF) alpha and highlighted the nanobody, which is the first approved product for the patients with rheumatoid arthritis (RA), ozoralizumab (OZR). Background for the clinical development, pharmakokinetics, and clinical trial data for OZR were shown. It has been approved in Japan in 2022 and marked as the fixth products of TNF inhibitors for RA in Japan. The similarities and differences among these products are discussed in this review.</div></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"72 ","pages":"Article 152693"},"PeriodicalIF":4.6,"publicationDate":"2025-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143781121","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development of a prediction model for poor prognosis in childhood-onset Takayasu's arteritis","authors":"Yingjie Xu ,&nbsp;Wenquan Niu ,&nbsp;Min Kang ,&nbsp;Jia Zhu ,&nbsp;Fan Liu ,&nbsp;Baoping He ,&nbsp;Weihong Chu ,&nbsp;Lian Wang ,&nbsp;Xue Zhao ,&nbsp;Gaixiu Su ,&nbsp;Dan Zhang ,&nbsp;Tong Yue ,&nbsp;Ming Li ,&nbsp;Jianming Lai ,&nbsp;Xiaohui Li","doi":"10.1016/j.semarthrit.2025.152711","DOIUrl":"10.1016/j.semarthrit.2025.152711","url":null,"abstract":"<div><h3>Objectives</h3><div>Childhood-onset Takayasu's arteritis (cTAK) is a rare disease with high recurrence rates, vascular complications, and mortality. This study aimed to identify the risk factors for poor prognosis in hospitalized patients with cTAK and develop a nomogram prediction model.</div></div><div><h3>Methods</h3><div>This was a prospective longitudinal multicenter cohort study. Cohorts were categorized into poor and good prognosis groups according to follow-up outcomes. Poor prognosis included vascular complications, disease recurrence, persistent non-remission, and cTAK-related death.</div></div><div><h3>Results</h3><div>Of the 111 patients, 73 (65.8%) and 38 (34.2%) were categorized into the good and poor prognosis groups, respectively, with a median follow-up of 36.0 [24.0, 60.0] months. Seven independent factors for poor prognosis of cTAK were identified: the Indian Takayasu Clinical Activity Score with the Acute-Phase Response (ITAS.A), internal carotid artery stenosis, external carotid artery stenosis, aortic insufficiency, mitral insufficiency, tricuspid insufficiency, and hypertensive heart disease (odds ratios: 1.20, 3.21, 3.57, 3.88, 9.08, 15.67, and 7.42, respectively; all <em>P</em> values &lt; 0.05). The nomogram prediction model yielded an area under the receiver operating characteristic curve of 0.79. The C-index of the nomogram constructed based on the prediction model was 0.73. The accuracy of this model was 67.0% after bootstrapping for 1000 repetitions.</div></div><div><h3>Conclusion</h3><div>We used easily accessible clinical and laboratory data to establish a nomogram model for predicting the probability of poor prognosis with hospitalized cTAK patients.</div></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"72 ","pages":"Article 152711"},"PeriodicalIF":4.6,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143725416","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incidence of aortic aneurysm, dissection, or rupture among patients with polymyalgia rheumatica and giant cell arteritis","authors":"Kylie Carlson ,&nbsp;Mahmut Kaymakci ,&nbsp;Sebastian E. Sattui ,&nbsp;Michael Putman","doi":"10.1016/j.semarthrit.2025.152714","DOIUrl":"10.1016/j.semarthrit.2025.152714","url":null,"abstract":"<div><h3>Background</h3><div>Patients with polymyalgia rheumatica (PMR) may have subclinical large vessel vasculitis. We compared the incidence of aortic complications in PMR and giant cell arteritis (GCA) to the general population.</div></div><div><h3>Methods</h3><div>A retrospective cohort study was performed of patients with PMR and GCA identified by ≥2 ICD-9/ICD-10-CM diagnostic codes and concurrent corticosteroid treatment in the US-based TriNetX database (2000–2024). Matched general population controls were identified (1:3 ratio). The primary outcome, aortic complications, was a composite of aortic aneurysm and dissection/rupture. Adjusted hazard ratios (aHR) were calculated using Cox proportional cause-specific hazard models with PMR as the referent category.</div></div><div><h3>Findings</h3><div>Of 57,336 patients, 17,327 had PMR, 4,734 had GCA, and 35,275 were matched controls. Median follow-up time was 3.74 years (interquartile range, 1.8–6.4). The incidence rate of any aortic complication per 1,000 person-years was highest for GCA (11.69), followed by PMR (6.78) and the general population (5.09). Compared to patients with PMR, patients with GCA had a higher risk of any aortic complication (aHR 1.87, 95 % confidence interval (CI) 1.58–2.21); the general population risk was similar (aHR 0.95, 95 % CI 0.84–1.06). In a sensitivity analysis, patients with PMR who later developed GCA had a risk similar to those initially diagnosed with GCA (aHR 0.85, 95 % CI 0.60–1.19).</div></div><div><h3>Interpretation</h3><div>Patients with PMR had a similar risk of large vessel complications compared to the general population and a lower risk compared to those with GCA. These results do not support screening for aortic inflammation among patients with PMR who lack features of GCA.</div></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"72 ","pages":"Article 152714"},"PeriodicalIF":4.6,"publicationDate":"2025-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143680101","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Polygenic risk scores for rheumatoid arthritis and idiopathic pulmonary fibrosis and associations with RA, interstitial lung abnormalities, and quantitative interstitial abnormalities among smokers","authors":"Gregory C McDermott ,&nbsp;Matthew Moll ,&nbsp;Michael H Cho ,&nbsp;Keigo Hayashi ,&nbsp;Pierre-Antoine Juge ,&nbsp;Tracy J Doyle ,&nbsp;Misti L Paudel ,&nbsp;Gregory L Kinney ,&nbsp;Vanessa L Kronzer ,&nbsp;John S Kim ,&nbsp;Lauren A O'Keeffe ,&nbsp;Natalie A Davis ,&nbsp;Elana J Bernstein ,&nbsp;Paul F Dellaripa ,&nbsp;Elizabeth A Regan ,&nbsp;Gary M Hunninghake ,&nbsp;Edwin K Silverman ,&nbsp;Samuel Y Ash ,&nbsp;Raul San Jose Estepar ,&nbsp;George R Washko ,&nbsp;Jeffrey A Sparks","doi":"10.1016/j.semarthrit.2025.152708","DOIUrl":"10.1016/j.semarthrit.2025.152708","url":null,"abstract":"<div><h3>Objective</h3><div>Genome-wide association studies (GWAS) facilitate construction of polygenic risk scores (PRSs) for rheumatoid arthritis (RA) and idiopathic pulmonary fibrosis (IPF). We investigated associations of RA and IPF PRSs with RA and high-resolution chest computed tomography (HRCT) parenchymal lung abnormalities.</div></div><div><h3>Methods</h3><div>Participants in COPDGene, a prospective multicenter cohort of current/former smokers, had chest HRCT at study enrollment. Using genome-wide genotyping, RA and IPF PRSs were constructed using GWAS summary statistics. HRCT imaging underwent visual inspection for interstitial lung abnormalities (ILA) and quantitative CT (QCT) analysis using a machine-learning algorithm that quantified percentage of normal lung, interstitial abnormalities, and emphysema. RA was identified through self-report and DMARD use. We investigated associations of RA and IPF PRSs with RA, ILA, and QCT features using multivariable logistic and linear regression.</div></div><div><h3>Results</h3><div>We analyzed 9,230 COPDGene participants (mean age 59.6 years, 46.4 % female, 67.2 % non-Hispanic White, 32.8 % Black/African American). In non-Hispanic White participants, RA PRS was associated with RA diagnosis (OR 1.32 per unit, 95 %CI 1.18–1.49) but not ILA or QCT features. Among non-Hispanic White participants, IPF PRS was associated with ILA (OR 1.88 per unit, 95 %CI 1.52–2.32) and quantitative interstitial abnormalities (adjusted β=+0.50 % per unit, <em>p</em> = 7.3 × 10⁻⁸) but not RA. There were no statistically significant associations among Black/African American participants.</div></div><div><h3>Conclusions</h3><div>RA and IPF PRSs were associated with their intended phenotypes among non-Hispanic White participants but performed poorly among Black/African American participants. PRS may have future application to risk stratify for RA diagnosis among patients with ILD or for ILD among patients with RA.</div></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"72 ","pages":"Article 152708"},"PeriodicalIF":4.6,"publicationDate":"2025-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143632028","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Application of factor D and other complement factors as systemic sclerosis-associated pulmonary hypertension: Comment of the article by Petrow et al","authors":"Xian-zhe Zhou ,&nbsp;Rong-hong Guo ,&nbsp;Yan-li Yang ,&nbsp;James Cheng-Chung Wei ,&nbsp;Ke Xu ,&nbsp;Li-yun Zhang","doi":"10.1016/j.semarthrit.2025.152713","DOIUrl":"10.1016/j.semarthrit.2025.152713","url":null,"abstract":"","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"72 ","pages":"Article 152713"},"PeriodicalIF":4.6,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143679244","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world evidence of the antifibrotic nintedanib in rheumatoid arthritis-interstitial lung disease. National multicenter study of 74 patients","authors":"Belén Atienza-Mateo ,&nbsp;Ana Serrano-Combarro ,&nbsp;Jesús Loarce Martos ,&nbsp;Nuria Vegas-Revenga ,&nbsp;María Martín López ,&nbsp;Santos Castañeda ,&nbsp;Rafael B. Melero-González ,&nbsp;Natalia Mena Vázquez ,&nbsp;Carmen Carrasco-Cubero ,&nbsp;Carolina Díez Morrondo ,&nbsp;David Castro Corredor ,&nbsp;Tomás Ramón Vázquez Rodríguez ,&nbsp;Andrea García Valle ,&nbsp;Gema Bonilla ,&nbsp;Marina Rodríguez López ,&nbsp;Ignacio Braña Abascal ,&nbsp;Sara María Rojas Herrera ,&nbsp;Juan C Sarmiento-Monroy ,&nbsp;Pablo Andújar Brazal ,&nbsp;Diego Ferrer ,&nbsp;Christian Omar Anchorena Diaz","doi":"10.1016/j.semarthrit.2025.152710","DOIUrl":"10.1016/j.semarthrit.2025.152710","url":null,"abstract":"<div><h3>Objective</h3><div>To assess the effectiveness and safety of the antifibrotic drug nintedanib in rheumatoid arthritis (RA)-related interstitial lung disease (ILD) and a progressive phenotype in clinical practice.</div></div><div><h3>Methods</h3><div>National Spanish multicenter study of RA-ILD patients to whom nintedanib was added due to progressive fibrosing ILD. Outcome variables were effectiveness, retention rate and safety. Forced vital capacity (FVC) evolution was the primary endpoint. A comparative study between our cohort and those RA-ILD patients included in the INBUILD trial (<em>n</em> = 89, 42 treated with nintedanib) was performed.</div></div><div><h3>Results</h3><div>A total of 74 patients (31 women/43 men) were collected, mean age of 69.3 ± 8.8 years. Median [IQR] ILD duration up to antifibrotic initiation was 51 [22–77.5] months. Besides corticosteroids (<em>n</em> = 54), nintedanib was used combined with cDMARD (<em>n</em> = 21), bDMARD (<em>n</em> = 46) and/or JAKi (<em>n</em> = 4) and monotherapy (<em>n</em> = 3). Mean FVC one year before nintedanib start was 81.9 ± 21.2 (% pred.), whilst mean baseline FVC was 73.7 ± 22.5 (% pred.). After a median follow-up of 15 [10–22, 4–9] months, no significant decline in mean FVC or DLCO values was observed. Moreover, the evolution of DLCO and FVC significantly differed from a predictive model that assumed their changes without the drug. The retention rate with nintedanib was 78.4 %. During the follow up, 16.7 % of patients showed ILD progression or progressive pulmonary fibrosis. Gastrointestinal adverse events were the most common reason for nintedanib discontinuation. Compared with INBUILD trial, patients from clinical practice were older, had a higher tobacco exposure, time since ILD diagnosis was longer and treatment with combined immunosuppressants was more frequent. However, baseline mean values of FVC and DLCO were similar in both groups.</div></div><div><h3>Conclusion</h3><div>Nintedanib seems to be effective and relatively safe in progressive fibrosing RA-ILD despite clinical differences with the INBUILD trial.</div></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"72 ","pages":"Article 152710"},"PeriodicalIF":4.6,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143674658","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness and safety of anti-CD20 monoclonal antibodies versus csDMARDs in anti-Jo-1 antisynthetase syndrome: A retrospective cohort study","authors":"Shuhui Sun ,&nbsp;Jiajia Jin ,&nbsp;Jie Chen ,&nbsp;Kaiwen Wang ,&nbsp;Wanlong Wu ,&nbsp;Xiaodong Wang ,&nbsp;Yanyan Song ,&nbsp;Shuang Ye","doi":"10.1016/j.semarthrit.2025.152712","DOIUrl":"10.1016/j.semarthrit.2025.152712","url":null,"abstract":"<div><h3>Objectives</h3><div>Anti-Jo-1 antisynthetase syndrome (Jo1⁺ASyS) is the most common form of idiopathic inflammatory myopathy with high relapse rates and limited treatment options beyond csDMARDs, which frequently fail to achieve adequate disease control. This study aimed to evaluate the efficacy and safety of anti-CD20 monoclonal antibodies (CD20mAbs) compared to conventional synthetic(cs) DMARDs in patients with Jo1⁺ASyS.</div></div><div><h3>Methods</h3><div>A single-center retrospective cohort of patients with Jo1⁺ASyS were collected at RenJi Hospital in China (2007–2023). A prevalent new-user design with time-based propensity scores, applied without replacement, was used to match CD20mAb and csDMARD users. The primary outcome was the percentage of patients reaching Low Disease Activity (5-item LDA), as defined by the absence of active arthritis, myositis, ILD, fever, and prednisone dosage ≤7.5 mg/day.</div></div><div><h3>Results</h3><div>A total of 166 eligible treatment regimens, including CD20mAbs and csDMARDs, were extracted from 128 Jo1⁺ASyS patients with a median follow-up period of 5 years. Utilizing propensity score, 49 pairs of individual prescriptions for CD20mAbs and csDMARDs users were matched. The group treated with CD20mAbs exhibited a significantly higher rate of achieving LDA compared to those treated with csDMARDs (46.9 % vs. 22.4 %, <em>p</em> = 0.011). No significant differences in exposure-adjusted incidence rate were detected between the two treatment modalities (CD20mAbs vs. csDMARDs = 7.911 vs. 6.479 per 100 patient-yr, RR = 1.22; 95 % CI: 0.64, 2.36), with respect to major infections. Sensitivity analyses further confirmed the robustness of the superior effectiveness of the CD20mAbs compared to the csDMARDs.</div></div><div><h3>Conclusion</h3><div>CD20mAbs exhibited remarkable treatment efficacy and acceptable safety in patients with Jo1⁺ASyS. Cumulative evidence, including ours suggested that CD20mAbs should be considered as a first-line option for Jo1⁺ASyS.</div></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"72 ","pages":"Article 152712"},"PeriodicalIF":4.6,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143680019","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Core domain set for chronic and/or recurrent manifestations of calcium pyrophosphate deposition disease: OMERACT delphi survey to establish consensus","authors":"Yiling Zhang ,&nbsp;Sara K. Tedeschi ,&nbsp;Abhishek Abhishek ,&nbsp;Owen Hensey ,&nbsp;David Grossberg ,&nbsp;Ken Cai ,&nbsp;Beverley Shea ,&nbsp;Jasvinder A. Singh ,&nbsp;Robin Christensen ,&nbsp;Teodora Serban ,&nbsp;Edoardo Cipolletta ,&nbsp;Konstantinos Parperis ,&nbsp;Cesar Diaz-Torne ,&nbsp;Geraldine M McCarthy ,&nbsp;Fabio Becce ,&nbsp;Tamer A Gheita ,&nbsp;Silvia Sirotti ,&nbsp;Sara Nysom Christiansen ,&nbsp;Luis Coronel ,&nbsp;Lisa K Stamp ,&nbsp;Nicola Dalbeth","doi":"10.1016/j.semarthrit.2025.152669","DOIUrl":"10.1016/j.semarthrit.2025.152669","url":null,"abstract":"<div><h3>Objective</h3><div>To agree on important domains for the Outcome Measures in Rheumatology (OMERACT) core domain set for chronic and/or recurrent manifestations of calcium pyrophosphate deposition (CPPD) disease.</div></div><div><h3>Methods</h3><div>Patient research partners (PRPs) and other participants (mainly clinicians and researchers) contributed to three rounds of a consensus survey using Delphi methodology. Consensus was defined if ≥70% of both patients and other participants scored the domain as ‘critically important domain to include’. In a subsequent ranking exercise, all participants were asked to select and rank up to 10 of the domains reaching consensus.</div></div><div><h3>Results</h3><div>Fifteen domains reached consensus as critically important. Within the Pathophysiological Manifestations area, these were joint pain, joint tenderness, joint swelling, acute CPP crystal arthritis flare, joint damage on imaging tests, joint calcification on imaging tests, and crystals in joint fluid. Within the Life Impact area, these were overall function, ability to complete daily tasks, ability to work, health related quality of life, patient global assessment response to treatment, patient global assessment of disease activity, physician global assessment of disease activity, and patient satisfaction with treatment. No domains within the Societal/Resource Use area reached consensus as critically important. In the ranking exercise, joint pain, joint tenderness, joint swelling, acute CPP crystal arthritis flare and overall function were most highly ranked.</div></div><div><h3>Conclusion</h3><div>This work has identified potential domains for the OMERACT core domain set for chronic and/or recurrent manifestations of CPPD disease. There was strong support for joint pain, joint tenderness, joint swelling, acute CPP crystal arthritis flare, overall function, and global assessments of disease activity as core domains.</div></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"72 ","pages":"Article 152669"},"PeriodicalIF":4.6,"publicationDate":"2025-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143611037","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}